Suganril

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suganril

What is Suganril? A Foundational Overview

Property Description
Active ingredient Piroxicam
Form Capsules, tablets, suppositories, topical gel/cream
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic (Oxicam derivative)

What Type of Medicine is Suganril?

Suganril is a synthetic medicinal entity containing the active ingredient Piroxicam. It is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), belonging specifically to the Oxicam subclass of anti-inflammatory agents. This high-level classification defines Suganril as a core therapeutic option intended to modulate the body's response to pain and inflammation. Piroxicam is used for reducing inflammation associated with musculoskeletal conditions.

Piroxicam’s differentiating factor is its relatively long plasma half-life, which is typically cited as approximately 40 to 50 hours, a characteristic that supports less frequent dosing intervals for sustained therapeutic effect. Suganril is clinically recognized for providing effective symptomatic relief in patients experiencing chronic pain.

Composition and Available Forms of Suganril

The fundamental composition is based on the single active ingredient, Piroxicam. A distinctive feature of some formulations is the use of the beta-cyclodextrin salt, which is a variation designed to enhance its absorption rate for a more rapid onset of action. Suganril is available in multiple pharmaceutical preparations, including oral dosage forms such as capsules and tablets, and preparations for topical application like gels or creams. The forms permit flexible routes of administration, allowing the substance to be delivered systemically or locally to the affected area, depending on the therapeutic need.

What is the General Purpose of Suganril?

The general purpose of Suganril is to provide symptomatic relief through its core anti-inflammatory and analgesic effects. Piroxicam achieves this by inhibiting the enzyme cyclooxygenase (COX), thereby suppressing the synthesis of prostaglandins. Prostaglandins are the biological messengers that mediate the pain and inflammatory response in the body, and their suppression generally helps to alleviate the associated symptoms of swelling, stiffness, and discomfort in the muscles and joints, as is common in chronic inflammatory conditions.

Regulatory References

  1. Piroxicam - LiverTox - NCBI Bookshelf

What side effects are possible with Suganril?

Possible Side Effects and Safety Information

Suganril (Piroxicam) is a Nonsteroidal Anti-Inflammatory Drug (NSAID) whose safety profile, as documented in official regulatory labeling, includes potential adverse reactions categorized by frequency and system-organ class. The most frequently reported adverse reactions, categorized as common in clinical trials (incidence ge 2%, per FDA data), primarily affect the Gastrointestinal System (nausea, abdominal pain, flatulence, constipation, diarrhea) and the Nervous System (headache, dizziness). Fluid retention (edema) and rash are also commonly documented.

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies serious, potentially life-threatening risks associated with NSAID use. These include the risk of serious cardiovascular thrombotic events, such as myocardial infarction (MI) and stroke, where the risk may increase with the duration of use. Serious gastrointestinal adverse events, including bleeding, ulceration, and perforation, can occur at any time without warning symptoms. Additionally, rare but severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented, with the highest risk period noted as the first weeks of treatment.

Population and Duration-Specific Notes

Specific populations face documented safety considerations: older adults are at a greater risk for serious gastrointestinal adverse events. Furthermore, the medicine is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Use during late-stage pregnancy (from 30 weeks gestation) is also advised against due to the risk of premature closure of the fetal ductus arteriosus. These constraints and patterns structure the official regulatory understanding of the medicine’s risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Suganril (Piroxicam) details the specific clinical manifestations and severe outcomes associated with acute overexposure, alongside mandatory emergency actions.

Documented Manifestations and Severe Outcomes An overdose may present with documented clinical signs such as nausea, vomiting, diarrhea, severe headache, confusion, agitation, and convulsions (seizures). More serious, life-threatening outcomes described in regulatory documents include acute gastrointestinal bleeding, ulceration, and perforation, which carry a risk of being fatal. Additional severe effects include acute renal failure (characterized by little to no urine production) and systemic events like shock or coma. The risk of serious adverse effects is noted to be increased in elderly individuals or those with pre-existing renal or hepatic impairment.

Mandatory Emergency Actions and Management Given the potential for serious complications, government guidance explicitly mandates that immediate medical attention must be sought for any suspected overdose. Emergency services must be contacted immediately if the person collapses, experiences a seizure, has trouble breathing, or cannot be awakened. Regulatory information confirms that no specific antidote is known for Piroxicam overexposure. Management is therefore strictly symptomatic and supportive, and may involve procedures such as the administration of activated charcoal, gastric lavage, and continuous monitoring of vital signs in a hospital setting.

Therapeutic Uses of Suganril

What Suganril Treats: Main Uses and Benefits

Suganril, containing the active ingredient piroxicam, is a medication belonging to the non-steroidal anti-inflammatory drug (NSAID) class. It is primarily used to manage symptoms associated with various inflammatory and degenerative conditions affecting the musculoskeletal system.

Primary Conditions Treated

Suganril is commonly utilized for the symptomatic relief of pain, swelling, and joint stiffness in the following conditions:

  • Osteoarthritis: A degenerative joint disease characterized by the breakdown of cartilage.
  • Rheumatoid Arthritis: An autoimmune condition that causes chronic inflammation of the joints.
  • Ankylosing Spondylitis: A type of inflammatory arthritis that primarily affects the spine and large joints.

Therapeutic Benefits

The medication works by inhibiting the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation. By targeting these processes, Suganril provides several clinical benefits:

  • Reduction of Inflammation: It helps decrease the swelling and redness associated with chronic joint disorders.
  • Pain Management: It alleviates persistent pain, which can improve daily functioning for individuals with long-term arthritic conditions.
  • Improved Mobility: By reducing stiffness and discomfort, it may help patients maintain a better range of motion in affected joints.

Because of its long half-life, the medication is typically noted for providing sustained relief over an extended period, which can be beneficial in managing the symptoms of chronic inflammatory diseases.

Regulatory References

  1. DailyMed / NIH Piroxicam Labeling Overview

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Suganril

Suganril (Piroxicam) eligibility is defined by official regulatory guidelines, restricting use primarily to adult populations with conditions such as Osteoarthritis or Rheumatoid Arthritis. The medicine is not approved for use in individuals under 18 years old.

Contraindicated Populations

Suganril is absolutely contraindicated in several patient groups. These prohibitions include individuals with a known allergy to Piroxicam or those with a history of allergic-type reactions to aspirin or other NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). Use is also prohibited for pain management following Coronary Artery Bypass Graft (CABG) surgery and in patients with active or a history of gastrointestinal ulceration or bleeding.

Restricted and Conditional Use

Eligibility is limited for patients with certain comorbidities. Use must be avoided in cases of advanced renal disease or severe heart failure, unless the benefits are determined to outweigh the risk of worsening function. Pregnant women must avoid use in the late stages of pregnancy, and the medicine is not recommended for nursing mothers. Elderly patients and those with hypertension require caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Suganril has documented interactions with several classes of medicinal products, which primarily affect the risk of bleeding, the efficacy of co-administered drugs, or the potential for increased toxicity. These constraints are detailed in official regulatory documents.


Clinically Significant Interacting Products

Product Class / Category Specific Examples Listed Primary Interaction Mechanism (Regulatory Basis)
Anticoagulants Warfarin Additive increase in the risk of bleeding or hemorrhage.
Antihypertensives Lisinopril, Losartan May reduce the blood pressure-lowering effect, potentially leading to treatment failure.
Other NSAIDs/Antiplatelets Aspirin (low-dose or high-dose) Avoidance is generally necessary due to significantly increased risk of gastrointestinal bleeding.
Corticosteroids Dexamethasone Increased risk of serious gastrointestinal ulceration and toxicity.
Fluoroquinolone Antibiotics (None specifically listed) Increased central nervous system (CNS) stimulation, which may lead to tremors or seizures.

Additional Constraints and Requirements

  • Alcohol: Consumption of alcohol is restricted due to a substantial, documented increase in the risk of stomach bleeding when used concurrently with Suganril.
  • Laboratory Tests: Suganril can interfere with diagnostic results by increasing bleeding time and modifying blood chloride and sodium levels.
  • Population Notes: Patients with pre-existing gastrointestinal toxicity require consultation before long-term use (beyond one month) due to the drug's interaction profile.

Mechanism of Action

Non-Selective Inhibition of the COX Enzyme System

The fundamental mechanism involves the active ingredient, Piroxicam, acting as a reversible, non-selective inhibitor of the Cyclooxygenase (COX) enzyme system (both COX-1 and COX-2). This molecular action halts the initial step of the Arachidonic Acid Cascade, thereby preventing the conversion of the substrate into key biological mediators.


Suppression of Prostaglandin Mediator Synthesis

By inhibiting the COX enzymes, the drug rapidly and profoundly suppresses the formation of pro-inflammatory messengers like Prostaglandins (especially PGE2) and Thromboxanes. This targeted suppression limits the availability of the molecules responsible for sensitizing peripheral nerve endings and promoting local vascular changes, which initiates the crucial anti-inflammatory and nociceptive signaling modulation physiological cascade.


Mechanistic Duality and Systemic Consequences

The mechanism modulates both peripheral and central pathways. Its action is largely peripheral, reducing mediator release at the site of biological disruption, but the suppression of PGE2 synthesis in the brain's hypothalamus also produces a central effect that mediates the reduction of elevated core body temperature. The drug's activity also includes a secondary, COX-independent effect that modulates neutrophil function, influencing the cellular aspects of the inflammatory response.

Dosage and Administration Information

How to Use Suganril

Suganril (Piroxicam) involves specific parameters concerning administration route, dosing, and frequency. The medicine is primarily available for oral administration as 10 mg or 20 mg capsules or tablets, but available routes also include topical (gel/cream) and, in some regions, rectal (suppository) or intramuscular (IM) injection.


Official Dosing and Scheduling

For chronic conditions such as osteoarthritis, the standard adult maintenance dose is 20 mg, administered once daily (qD). This once-daily schedule is supported by Piroxicam's long half-life, which enables a sustained therapeutic level. The total maximum daily dose for chronic use is restricted to 20 mg.

In contrast, treatment for acute symptomatic episodes, like a gout attack, typically begins with a higher initial dose of 40 mg daily for the first one or two days, which is then immediately reduced to the 20 mg daily dose for the remainder of the short course. Treatment via IM injection, when used, is generally limited to 2 to 3 days, followed by a switch to an oral or rectal form.


Administration Context and Special Conditions

Oral forms of Suganril should be taken with or immediately after food or with a significant amount of water (8 to 12 ounces) to support proper administration. Capsules must be swallowed whole. Due to the drug's long half-life, the full therapeutic benefit is typically not assessed for at least two weeks after starting treatment, as steady-state blood levels may take up to 7 to 12 days to be reached. For older adults and patients with impaired organ function, the use of the lowest effective dose is generally considered.

Recent Clinical Evidence

Research evidence / Overview of studies for Suganril


Evidence for use in Chronic Inflammatory Conditions (OA, RA, and AS)

Research has predominantly used Randomized Controlled Trials (RCTs) and systematic reviews applied in studies examining patient-reported experiences related to chronic inflammatory conditions, specifically osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). These studies included adults with conditions marked by functional limitations and aimed to measure outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Research exploring Suganril in the context of symptomatic assessment focused on how symptoms evolved in the observed populations, and findings describe patterns observed in the studies regarding changes in patient-reported pain intensity and functional scores over defined time intervals. Suganril was evaluated in comparisons against other medicines, and data show patterns related to how symptoms were monitored during the research period.

However, the existing research, which generally had short- to intermediate-term follow-up durations, provides limited insight into long-term changes. There is limited information for long-term outcomes, as follow-up durations were limited relative to the chronic nature of these diseases.

Evidence for use in Acute Pain and Inflammation

Suganril was studied for acute pain situations, including acute musculoskeletal flares and primary dysmenorrhea, which are conditions involving periods of heightened symptoms. The research explored short-term symptom changes, primarily using Placebo-controlled RCTs where outcomes describing episodic or acute changes were measured. Studies were conducted during periods of increased symptom activity, and research examined the onset and magnitude of changes in outcomes related to physical discomfort. Findings from these acute-setting trials describe patterns observed in the studies related to the difference in how discomfort levels evolved compared to an inactive substance. Research provides context but not individual predictions regarding the rapid attainment of measurable symptomatic change.


What is Still Uncertain About Suganril Research

Research indicates that certainty remains low in several areas that are important for fully understanding the medicine. Data for certain groups remain insufficient, and the evidence quality varies across studies, particularly when reviewing older trials. There is limited information for long-term outcomes, as the follow-up durations were limited in the pivotal RCTs. Evidence remains limited for specific subgroups of patients. Research describes that while older adults were included in some trials, data are still emerging regarding patterns of observed change in those with significant co-occurring conditions.

Key Studies & References

  1. Piroxicam Drug Label and Prescribing Information
  2. Guidelines for the management of Osteoarthritis of the knee and hip

Frequently Asked Questions (FAQ)

Common questions about Suganril (FAQ)


Q: Is Suganril considered a muscle relaxant or a narcotic painkiller?

According to official product information, Suganril is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It works by reducing inflammation and pain through specific enzyme inhibition. It is neither a muscle relaxant nor is it classified as a narcotic or habit-forming painkiller.


Q: Is it normal to feel dizzy or drowsy after taking Suganril?

Official safety data indicates that dizziness is commonly reported as an adverse reaction in clinical studies. Drowsiness has also been reported by some users. Patients should be aware of these potential effects.


Q: Can Suganril be taken for pain relief on an 'as-needed' basis?

Official product information emphasizes sustained therapy or short-course treatment for acute flare-ups due to the drug's long half-life. Individualized dosing frequency, including any flexible scheduling, should be discussed with a healthcare provider.


Q: Why is Suganril sometimes prescribed for conditions like rheumatoid arthritis and osteoarthritis?

Suganril is approved for the management of the symptoms of these chronic inflammatory conditions. It is prescribed to relieve the associated pain, tenderness, swelling, and stiffness, and is intended to help improve physical function.


Q: What happens if I miss a scheduled dose of Suganril?

Official information suggests that if a dose is missed, it may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is typically skipped. The aim is to maintain the correct dosing interval and avoid taking two doses too close together.


Q: Is it safe to consume alcohol while I am taking Suganril?

Regulatory warnings state that alcohol consumption concurrently with the medicine may substantially increase the risk of stomach bleeding and gastrointestinal harm. This is a documented safety concern for patients taking this medication.


Q: Can Suganril be used to manage menstrual cramps or period pain?

Official medicine databases sometimes list Piroxicam, the active ingredient in Suganril, as an option used to relieve menstrual pain (dysmenorrhea). This aligns with its primary use in managing acute, painful inflammatory conditions.


Q: What are the precautions for elderly patients taking Suganril?

Official information advises that elderly patients are generally at a greater risk for serious gastrointestinal adverse events and potential kidney issues. For this reason, official instructions note that using the lowest effective dose is a key consideration for managing safety in this population.


Q: Can Suganril pass into breast milk, and what is the general recommendation for breastfeeding mothers?

Piroxicam, the active ingredient, is known to be excreted into human milk. Official guidance indicates that a healthcare provider must weigh the potential benefits of the medicine against the potential risk to the nursing child before making a decision.


Q: Are there known interactions between Suganril and common over-the-counter painkillers like paracetamol (acetaminophen)?

Some drug interaction sources indicate that combining Suganril with other painkillers, such as acetaminophen, may potentially increase the risk or severity of certain adverse effects. All medicines, including over-the-counter products, should be reviewed by a healthcare provider.


Q: Can Suganril be used for short-term pain, or is it better for chronic pain management?

Suganril is approved and effective for both. It is used in long-term management of chronic diseases like arthritis and is also used for the short-term treatment of acute exacerbations. The required dosing may differ depending on the type of pain being addressed.


Q: Will Suganril make me feel 'high' or is it considered habit-forming?

No. Suganril is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not a controlled substance. It has no narcotic properties and is not considered habit-forming.


Q: Is it common to experience swelling (edema) in the feet or hands while taking Suganril?

Yes, swelling of the face, hands, feet, or lower legs (edema) is a commonly documented adverse effect associated with Suganril use. This is a recognized side effect of NSAIDs.


Q: What are the signs of a potential overdose of Suganril?

Signs of a potential overdose can include nausea, vomiting, stomach pain, or black and bloody stools. In rare cases, more serious effects on the nervous system, such as confusion or seizures, may also be seen. Immediate medical attention is necessary if an overdose is suspected.


Q: What does it mean that Suganril is a 'non-selective COX inhibitor'?

This term refers to how the medicine works in the body. Suganril is described as blocking, or inhibiting, the activity of both the COX-1 and COX-2 enzymes. This dual inhibition is the definition of a non-selective inhibitor, which helps to reduce inflammation and pain.


Q: Can Suganril be used to treat acute gout attacks?

Yes, Piroxicam, the active ingredient, has established effectiveness for treating painful inflammatory conditions. It is sometimes used for the short-term relief of symptoms associated with acute gout attacks.


Q: Does the time of day matter when taking Suganril?

Official administration instructions often emphasize taking the medication at approximately the same time every day. This practice helps the body maintain consistent, steady levels of the medicine, which is especially important for chronic symptom management.


Q: Can taking Suganril cause ringing in the ears (tinnitus)?

Official adverse reaction data has documented that ringing or buzzing in the ears (tinnitus) is a side effect reported with the use of Suganril.


Q: Is there a link between Suganril and fluid retention in the body?

Yes, fluid retention (edema) is a commonly documented adverse effect. This potential effect is why caution is advised for patients with certain heart conditions, as fluid retention can sometimes worsen these conditions.


Q: Does Suganril affect blood sugar levels, which is a concern for diabetic patients?

Official adverse event reporting has documented that the active ingredient has been associated with changes in blood sugar. Both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar) have been reported as adverse experiences.


Q: Is Suganril a sulfa-containing drug, and does that matter for people with allergies?

Suganril is an Oxicam derivative and contains a sulfur dioxide group as part of its chemical structure. However, it is not considered a sulfonamide-class (sulfa) antibiotic. Individuals with a known allergy to other sulfonamide-containing medicines should consult with a healthcare professional regarding their specific circumstances.


Q: Can I donate blood while I am taking a prescription for Suganril?

Many blood donation guidelines indicate that donation is generally acceptable after a short waiting period following the last dose of an NSAID. Eligibility for donation is determined by the blood donation center and should be confirmed directly with them.


Q: How long does it typically take for Suganril to start working for joint stiffness?

Clinical trials show that therapeutic effects are evident relatively early in the course of treatment. However, the full, continuous benefit requires stable drug levels in the blood, which takes time to achieve.


Q: When can I expect the full effect of Suganril to be noticeable for chronic conditions?

Because the active ingredient has a long half-life, it takes time to reach a steady concentration in the body. The full therapeutic benefit for chronic conditions is generally noticeable after 8 to 12 weeks of continuous treatment.


Q: Can Suganril be taken with food, and does it help reduce stomach upset?

Official instructions advise that Suganril can be administered with or immediately after food or with plenty of water. Taking it with food is done specifically to help minimize gastrointestinal (GI) irritation.


Q: Are there any major risks associated with long-term use of Suganril?

Yes, regulatory warnings note that long-term use may increase the risk of serious cardiovascular thrombotic events, such as heart attack and stroke. It also increases the risk of serious gastrointestinal adverse events, including bleeding and perforation.


Q: Can Suganril cause an increase in blood pressure?

Official adverse event reporting has documented that hypertension (high blood pressure) is a reported adverse reaction. This is one reason why caution is advised for patients with existing high blood pressure.


Q: Is it true that Suganril can reduce the effect of diuretics (water pills)?

Yes, official drug interaction data indicates that NSAIDs, including Suganril, can reduce the therapeutic effects of certain diuretic and blood pressure medications. This means the water pill may not work as effectively if taken together.


Q: Can I drive or operate machinery if I experience dizziness from Suganril?

Official documentation advises that activities requiring mental alertness, such as driving or operating heavy machinery, should be avoided if adverse reactions like dizziness or drowsiness occur.


Q: How does Suganril affect patients who have kidney or liver conditions?

Official product information notes that the medicine is typically not used in patients with advanced kidney disease. For those with liver (hepatic) disease, a healthcare provider may need to consider dose adjustments. Caution and monitoring are advised for all patients with impaired organ function.

How should Suganril be stored and disposed of?

How to Store and Dispose of Suganril

Suganril (Piroxicam) must be stored according to regulatory requirements to maintain its stability and ensure safety. The medication must be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from moisture and excessive heat.

Storage and Protection

The product must be stored in its original, tightly closed container and kept out of the sight and reach of children. It should not be used past the expiration date, and non-solid forms should be kept from freezing.

Disposal Guidelines

Disposal of unused or expired Suganril should be done through a drug take-back program. If one is unavailable, the medicine must be prepared for household trash by mixing it with an undesirable substance and sealing it in a container. Do not flush the medicine down the toilet or throw it directly into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suganril found in:

A-Z Index: